Estrogen-receptor-positive HER-2-negative advanced breast cancer patients had significantly improved progression-free survival when treated with an oral combination regimen consisting of gairdrestrant, a novel, next-generation selective estrogen receptor degrader, and full antagonist, compared to a standard combination approach. These findings from the Phase 3 AVERA breast cancer study are presented today by Dr. Erica Meyer of Dana-Farber Cancer Institute at the annual meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany.
Please follow and like us:
